DV
Dividend Vision

ISLMF — ISLMF

ISLMF (ISLMF)

Total return is -42.1% over the past 0.3 years, 51.5 points behind SPY at 9.4%.

InSilico Medicine Cayman TopCo applies artificial intelligence to drug discovery and development through its proprietary Pharma.AI platform, which provides services including target identification, small molecule generation, and clinical outcome prediction across therapeutic areas such as fibrosis, oncology, and immunology. The company operates globally with strategic collaborations including agreements with Takeda, Suzhou Ribo Life Science, and Human Life Foundation Models. As an operating company with an inception date in 2026, distribution information is not currently available.

ISLMF key facts

Asset type
Stock
Asset class
Equity
Inception date
04/22/2026
Distribution frequency
None
Last close
$5.65
Average volume
17057.0
Payout ratio
0.0
Forward P/E
0.0